Peptide deformylase activated prodrugs

Details Peptide deformylase activated prodrugs Peptide deformylase activated prodrugs

2007-01-16

2007-01-16

Lukton, David (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S018700, C530S331000

Reexamination Certificate

active

10142089

ABSTRACT:
This invention provides a method for inhibiting the growth of a microorganism that expresses Peptide Deformylase by contacting the microorganism with an effective amount of the compound described herein. This method inhibits the growth of gram-positive and gram-negative microorganism, e.g.,S. aureus, S. epidermidis, K. pneumoniae, E. aerogenes, E. cloacae, M. catarrhalis, E. coli, E. faecalis, H. influenzaeandP. aeruginosa. This method can be practiced in vitro, ex vivo and in vivo. Further provided is a method for alleviating the symptoms of an infection by a Peptide Deformylase expressing microorganism in a subject by administering or delivering to the subject an effective amount of the compound described above.

REFERENCES:
patent: 4053638 (1977-10-01), Litchfield et al.
patent: 4071511 (1978-01-01), Takemoto et al.
patent: 4083974 (1978-04-01), Turi
patent: 4339440 (1982-07-01), Gjerløv
patent: 4415590 (1983-11-01), Gerzon
patent: 4427660 (1984-01-01), Schiffman et al.
patent: 5274113 (1993-12-01), Kang et al.
patent: 5350681 (1994-09-01), Iacobucci et al.
patent: 5918568 (1999-07-01), Gjerl.o slashed.v
patent: 6110908 (2000-08-01), Guthery
patent: 6143790 (2000-11-01), Hallinan et al.
patent: 6159706 (2000-12-01), Shepard
patent: 6245750 (2001-06-01), Shepard
patent: 6339151 (2002-01-01), Shepard et al.
patent: 6448058 (2002-09-01), Patel et al.
patent: 6613879 (2003-09-01), Firestone et al.
patent: WO 98/13059 (1998-04-01), None
patent: WO 99/08110 (1999-02-01), None
patent: WO 99/37753 (1999-07-01), None
patent: WO 01/07454 (2001-02-01), None
patent: WO 03/088913 (2003-10-01), None
patent: WO 2004/43400 (2004-05-01), None
Apfel, C. et al. “Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents” J. Med. Chem. (2000) 43:2324-2331.
Apfel, C.M. et al. “Peptide deformylase as an antibacterial drug target: Assays for detection of its inhibition inEscherichia colicell homogenates and intact cells” Anti. Agents and Chemo. (Apr. 2001a) 45(4):1053-1057.
Apfel, C.M. et al. “Peptide deformylase as an antibacterial drug target: Target validation and resistance development” Anti. Agents and Chemo. (Apr. 2001b) 45(4):1058-1064.
Becker, A. et al. “Iron center, substrate recognition and mechanism of peptide deformylase” Nat. Struct. Biol. (Dec. 1998) 5(12):1053-1058.
Chan, M. K. et al. “Crystal structure of theEscherichia colipeptide deformylase” Biochem. (1997) 36:13904 13909.
Chen D.Z. et al. “Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor” Biochem. (2000) 39(6):1256-1262.
Clements, J.M. et al. “Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor” Anti. Agents and Chemo. (Feb. 2001) 45(2):563-570.
de Groot, F.M.H. et al. “Synthesis and biological evaluation of 2′-carbamate-linked and 2′-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin” J. Med. Chem. (2000) 43:3093-3102.
Durand, D.J. et al. “Peptide aldehyde inhibitors of bacterial peptide deformylases” Arch. Biochem. & Biophysics. (Jul 15, 1999) 367(2): 297-302.
Giglione, C. et al. “Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents” Mol. Microbiol. (2000a) 36(6):1197-1205.
Giglione, C. et al. “Identification of eukaryotic peptide deformylases reveals universality of N-terminal protein processing mechanisms” EMBO J. (2000b) 19(21):5916-5929.
Hao, B. et al. “Structural basis for the design of antibiotics targeting peptide deformylase” Biochem. (1999) 38(15):4712-4719.
Hu, Y.J. et al. “H-phosphonate derivatives as novel peptide deformylase inhibitors” Bioorg Med Chem Letts. (1998) 8(18):2479-2482.
Huntington, K.M. et al. “Synthesis and antibacterial activity of peptide deformylase inhibitors” Biochem. (2000) 39(15):4543-4551.
Jayasekera, M.M.K. et al. “Novel nonpeptidic inhibitors of peptide deformylase” Arch. Biochem. & Biophys. (Sep. 15, 2000) 381(2):313-316.
Meinnel, T. et al. “Methionine as translation start signal: A review of the enzymes of the pathway inEscherichia coli” Biochimie. (1993) 75(12):1061-1075.
Ragusa S., et al. “Control of peptide deformylase activity by metal cations” J.Mol.Biol. (1998) 280:515-523.
Rajagopalan, P.T.R. et al. “Purification, characterization, and inhibition of peptide deformylase fromEscherichia coli” Biochem. (1997) 36(45):13910-13918.
Rajagopalan, P.T.R. et al. “Oxygen-mediated inactivation of peptide deformylase” J. Biol. Chem. (Aug. 28, 1998) 273(35):22305-22310.
Wei Y. and D. Pei “Continuous spectrophotometric assay of peptide deformylase” Anal Biochem. (1997) 250(1):29-34.
Wei, Y. et al. “Identification of a potent peptide deformylase inhibitor from a rationally designed combinatorial library” J Comb Chem. (2000) 2(6):650-657.
Wei, Y. and D. Pei “Activation of antibacterial prodrugs by peptide deformylase” Bioorg Med Chem Letts. (2000b) 10(10):1073-1078.
Lackey, D.B et al. “Enzyme-Catalyzed Therapeutic Agent (ECTA) Design: Activation of the Antitumor ECTA Compound NB 1011 by Thymidylate Synthase”Biochem Pharm. (2001) 61:179-189.
Dubowchick, G.M. et al. “Cathepsin B-Sensitive Dipeptide Prodrugs. 1. A Model Study of Structural Requirements for Efficient Release of Doxorubicin”Bioorg.&Med. Chem Letters(1998) 8(23):3341-3346.
de Groot, F.M.H. et al. “Elongated Multiple Electronic Cascade and Cyclization Spacer Systems in Activatible Anticancer Prodrugs for Enhanced Drug Release”J. Org. Chem. (2001) 66:8815-8830.
Carl, P.L. et al. “A Novel Connector Linkage Application in Prodrug Design”J. Med.Chem. (May 1981) 24(5):479-480.
Toki, B.E. et al. “Protease-Mediated Fragmentation of ρ-Amidobenzyl Ethers: A New Strategy for the Activation of Anticancer Prodrugs”J. Org. Chem. (2002) 67:1866-1872.
Niculescu-Duvaz, D. et al. “Self-Immolative Nitrogen Mustard Prodrugs for Suicide Gene Therapy”J. Med. Chem. (1998) 41:5297-5309.
Boduszek, B. “Synthesis of Novel Phosphonopeptides Derived from Pyridylmethylphosphonate Diphenyl Esters”Casreact. (2001) 136:279691.
de Groot, F.M.H. et al. “Synthesis and Biological Evaluation of Novel Prodrugs of Anthracyclines for Selective Activation by the Tumor-Associated Protease Plasmin”J. Med. Chem. (1999) 42(25):5277-5283.
Liu, X.-J. et al. “Synthesis and Anticancer Activities of New 5-fluorouracil-1-yl Phosphonotripeptides”Casreact. (2002) 138:106974.
Meinnel, T. “Vers une conception rationnelle de nouveaux agents antibactériens”Pathol. Biol. (Oct. 1999) 47(8):780-783.
International Search Report dated Jan. 17, 2003 for PCT/US2002/014500.
Written Opinion dated Jun. 6, 2003 for PCT/US2002/014500.
International Preliminary Examination Report dated Oct. 31, 2003 for PCT/US2002/014500.

Affiliated with

Also associated with

Rating

Peptide deformylase activated prodrugs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptide deformylase activated prodrugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide deformylase activated prodrugs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3798233